Piśmiennictwo :
1. Flisiak R., Horban A., Jaroszewicz J., Kozielewicz D., Pawłowska M., Parczewski M., Piekarska A., Simon K., Tomasiewicz K., Zarębska-Michaluk D.: Recommendations of management in SARS-CoV-2 infection of the Polish Association of Epidemiologists and Infectiologists. Pol. Arch. Intern. Med. 2020 2020; 130: 352-357; https://www.mp.pl/paim/en/node/15270/pdf2. Beigel J.H., Tomashek K.M., Dodd L.E. i wsp.: Remdesivir for the Treatment of Covid-19 - Preliminary Report. published on May 22, 2020, at NEJM.org.DOI:10.1056/NEJMoa2007764
3. FDA issuance of emergency use authorization for potential COVID-19 treatment. May 1, 2020 https://www.fda.gov/media/137564/download
4. EMA. Summary on compassionate use for Remdesivir Gilead (PDF/2.32 MB) (updated). https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivirgilead_en.pdf
5. Arechin – charakterystyka produktu leczniczego. http://www.urpl.gov.pl/sites/default/files/Arechin%20Charakterystyka%20Produktu%20L eczniczego.pdf
6. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z.: Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020; 18: 1094-1099.
7. Ye M., Fu D., Ren Y. i wsp.: Treatment with convalescent plasma for COVID-19 patients in Wuhan, China [published online ahead of print, 2020 Apr 15]. J Med Virol 2020; doi:10.1002/jmv.25882
